Literature DB >> 20627386

Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.

J Winkler, D Rech, S Kallert, J Rech, N Meidenbauer, W Roesler, A Mackensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20627386     DOI： 10.1016/j.leukres.2010.04.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  15 in total

Review 1.  Myelodysplastic Syndromes: Updates and Nuances.

Authors:  Kim-Hien T Dao
Journal:  Med Clin North Am       Date:  2017-03       Impact factor: 5.456

2.  Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.

Authors:  Guiyun Song; Benigno C Valdez; Yang Li; Yan Liu; Richard E Champlin; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2014-08-09       Impact factor: 5.742

3.  Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.

Authors:  Manish Sharma; Farhad Ravandi; Ulas Darda Bayraktar; Alexandre Chiattone; Qaiser Bashir; Sergio Giralt; Julianne Chen; Muzaffar Qazilbash; Partow Kebriaei; Marina Konopleva; Michael Andreeff; Jorge Cortes; Deborah McCue; Hagop Kantarjian; Richard E Champlin; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-20       Impact factor: 5.742

4.  Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

Authors:  Yi-Bin Chen; Shuli Li; Andrew A Lane; Christine Connolly; Candice Del Rio; Betsy Valles; Morgan Curtis; Karen Ballen; Corey Cutler; Bimalangshu R Dey; Areej El-Jawahri; Amir T Fathi; Vincent T Ho; Amy Joyce; Steven McAfee; Michelle Rudek; Trivikram Rajkhowa; Sigitas Verselis; Joseph H Antin; Thomas R Spitzer; Mark Levis; Robert Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-17       Impact factor: 5.742

Review 5.  Remaining challenges in childhood cancer and newer targeted therapeutics.

Authors:  Malcolm A Smith; Gregory H Reaman
Journal:  Pediatr Clin North Am       Date:  2014-10-18       Impact factor: 3.278

Review 6.  Will newer tyrosine kinase inhibitors have an impact in AML?

Authors:  Mark J Levis
Journal:  Best Pract Res Clin Haematol       Date:  2010-11-05       Impact factor: 3.020

7.  Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party.

Authors:  Ali Bazarbachi; Myriam Labopin; Giorgia Battipaglia; Azedine Djabali; Jakob Passweg; Gerard Socié; Edouard Forcade; Didier Blaise; Patrice Chevallier; Corentin Orvain; Jan J Cornelissen; William Arcese; Sylvain Chantepie; Khowla Hashaishi; Jean El Cheikh; Michael Medinger; Jordi Esteve; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

8.  A proposal regarding reporting of in vitro testing results.

Authors:  Malcolm A Smith; Peter Houghton
Journal:  Clin Cancer Res       Date:  2013-04-11       Impact factor: 12.531

9.  OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.

Authors:  Xiangxuan Zhao; Changhai Tian; William M Puszyk; Olorunseun O Ogunwobi; Mengde Cao; Ton Wang; Roniel Cabrera; David R Nelson; Chen Liu
Journal:  Lab Invest       Date:  2012-10-29       Impact factor: 5.662

Review 10.  Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Amir T Fathi; Yi-Bin Chen
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.